The Changing Landscape for Stroke\ua0Prevention in AF: Findings From the GLORIA-AF Registry Phase 2

Background GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non\u2013vitamin K antagonist oral anticoagulant (NOAC), became available. Objectives This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase 1. Methods During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis describes eligible patients\u2019 baseline characteristics. Atrial fibrillation disease characteristics, medical outcomes, and concomitant diseases and medications were collected. Data were analyzed using descriptive statistics. Results Of the total patients, 45.5% were female; median age was 71 (interquartile range: 64, 78) years. Patients were from Europe (47.1%), North America (22.5%), Asia (20.3%), Latin America (6.0%), and the Middle East/Africa (4.0%). Most had high stroke risk (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age  6575 years, Diabetes mellitus, previous Stroke, Vascular disease, Age 65 to 74 years, Sex category] score  652; 86.1%); 13.9% had moderate risk (CHA2DS2-VASc = 1). Overall, 79.9% received oral anticoagulants, of whom 47.6% received NOAC and 32.3% vitamin K antagonists (VKA); 12.1% received antiplatelet agents; 7.8% received no antithrombotic treatment. For comparison, the proportion of phase 1 patients (of N = 1,063 all eligible) prescribed VKA was 32.8%, acetylsalicylic acid 41.7%, and no therapy 20.2%. In Europe in phase 2, treatment with NOAC was more common than VKA (52.3% and 37.8%, respectively); 6.0% of patients received antiplatelet treatment; and 3.8% received no antithrombotic treatment. In North America, 52.1%, 26.2%, and 14.0% of patients received NOAC, VKA, and antiplatelet drugs, respectively; 7.5% received no antithrombotic treatment. NOAC use was less common in Asia (27.7%), where 27.5% of patients received VKA, 25.0% antiplatelet drugs, and 19.8% no antithrombotic treatment. Conclusions The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in Asia and North America. (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation [GLORIA-AF]; NCT01468701

Plasticité du cerveau et maintien de l’activité

Vivre, c’est vieillir, et cesser de vieillir, c’est cesser de vivre.Tacite Tout au long de la vie, les cellules qui composent les organes du corps sont altérées, meurent et sont éliminées. Normalement, cette mort est compensée par des divisions de cellules souches et de nouvelles cellules remplacent les cellules perdues. Les fonctions des organes sont ainsi maintenues mais elles se détériorent avec la diminution progressive de l’efficacité du processus de renouvellement. Cette dérive du proce..

Paired Helical Filaments in Spinal Ganglion Neurons of Elderly Rats

Ultrastructural study of spinal ganglion neurons in elderly rats (aged from 24 to 32 months) allowed the observation of spontaneously occurring paired helical filaments (PHFs). On the basis of this finding the rat may provide an animal model for the study of the morphogenesis and nature of the PHFs which are characteristic of human senile dementia of the Alzheimer type

Heparin treatment increases 9-kb MAP2 mRNA levels in neuronal cell cultures

When neuronal adhesion is reduced by heparin, cultured neurons detach from the substratum and form clusters connected by neuritic fascicles. 24 h after treatment, Northern blots analysis revealed an increase in the expression of the 9-kb MAP2 mRNA in the heparin-treated neuronal cultures. MAP2 being associated with the cross-bridges between microtubules, this increased expression could be an attempt of the cells to rigidify their cytoskeleton to compensate for the reduced attachment. However, the MAP2 protein content was not increased after a 24-h heparin treatment. We discuss possible explanations for this observation and their implications on MAP2 metabolism

Darwinismes et spécificité de l'humain

L’homme n’est-il qu’un animal parmi d’autres ? La théorie darwinienne de l’évolution des espèces renouvelle les termes de cette question aux retentissements multiples. L’objet de l’ouvrage est de mettre à portée d’un large public un exposé des connaissances scientifiques en un domaine où prolifèrent fantasmes et simplismes. Pour y voir clair dans la théorie scientifique comme dans l’idéologie des différents darwinismes, le savoir du biologiste est essentiel mais ne suffit pas : neurosciences, anthropologie, sociologie, histoire, philosophie des sciences et théologie sont appelées à croiser leur apport pour s’ajuster à la complexité des enjeux. Sciences naturelles et sciences humaines engagent le dialogue. L’approche interdisciplinaire de cet ouvrage signifie pour les différentes disciplines une initiation au langage de l’autre et donc aussi un accès à la conscience de leurs propres limites. Par cette conversation, les savoirs font l’expérience de leur appartenance commune à une quête plus large du vrai